Publications

Plusieurs projets de recherche ont déjà bénéficié des ressources de la BGC, donnant lieu à des publications dans des revues scientifiques :

2024

• Hodel F, et al. Prevalence of actionable pharmacogenetic variants and high-risk drug prescriptions: A Swiss hospital-based cohort study. Clin Transl Sci. 2024 Sep;17(9):e70009.
• Thorball C, et al. Polygenic risk score associations with immune checkpoint inhibitors related endocrine toxicity. Annals of Oncology. 2024;35:S240–1.
• de Joode K, et al. Effects of CTLA-4 Single Nucleotide Polymorphisms on Toxicity of Ipilimumab-Containing Regimens in Patients With Advanced Stage Melanoma. Journal of Immunotherapy 47(5):p 190-194, June 2024. DOI: 10.1097/CJI.0000000000000506

Avant 2024

• Porcu E, et al. A polygenic risk score to predict sudden cardiac arrest in patients with coronary artery disease. medRxiv 2022.07.26.22278069.
• Redin C, et al. The «Amish» NM_000256.3:c.3330+2T>G splice variant in MYBPC3 associated with hypertrophic cardiomyopathy is an ancient Swiss mutation. Eur J Med Genet. 2022 Dec;65(12):104627.
• Maurer F, et al. Identification and molecular characterisation of Lausanne Institutional Biobank participants with familial hypercholesterolaemia - a proof-of-concept study. Swiss Med Wkly. 2016 Aug 6;146:w14326. 
• Mooser V, et al. The Lausanne Institutional Biobank: a new resource to catalyse research in personalised medicine and pharmaceutical sciences. Swiss Med Wkly. 2014 Dec 4; 144: w14033.